In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first human trial testing a potential COVID-19 vaccine has been successful, with initial results suggesting the vaccine is safe and capable of generating an immune response against SARS-CoV-2 in humans.
Researchers at the Korea Institute of Science and Technology (KIST) and Catholic University of Korea (CUK) have developed a vaccine platform against MERS coronavirus (MERS-CoV) that could be used to develop a vaccine for COVID-19.
A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
In this blog, we review some of the main targets of universal vaccines and the key challenges to their successful implementation.
A mouse study has revealed that obesity may be one factor explaining the significant amount of variation in the influenza virus each year, likely due to an impaired interferon defense response.
The National Institute of Allergy and Infectious Diseases has stopped administering an experimental HIV vaccine in the South Africa HVTN 702 clinical trial, after an independent data and safety monitoring board has found that the vaccine is ineffective at preventing HIV infection.
Optimizing vaccine models for Streptococcus pneumoniae suggests that vaccine programs need to be tailored to target specific subgroups including age and geographical region.